No later than the first quarter of 2021, Mexico could have access to the Covid-19 vaccine made by the American Pharmaceutical Pfizer. Photo: Reuters
By the first quarter of 2021 at the latest, Mexico could have access to the Covid-19 vaccine made by the American Pharmaceutical Pfizer, reported Alejandro Cané, Scientific and Medical Affairs Leader for North America of Pfizer’s Vaccines Division.
From Argentina, in an exclusive interview with Excelsior, the clinical researcher indicated that at the end of November, it is planned to deliver the information, efficacy, safety, quality and manufacturing package of phase three of the clinical trial that is developed in conjunction with the German biotechnology company Biontech, so that the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) make their evaluation and issue the “authorization for use in emergency situations”.
Alejandro Cané explained that -even- if the vaccines are authorized this year, Pfizer will begin – immediately and before the end of 2020 – the distribution of 50 million doses that it has already prepared, which will be distributed among the countries with which that already has pre-purchase agreements, like Mexico.
“We have signed agreements with different governments around the world, not only with the Mexican Government, to supply vaccines on a schedule that goes from regulatory approval until the first quarter of next year.
“Our schedule is to have around 50 million doses available to distribute in 2020 and one point 3 billion doses throughout 2021.
“Obviously this is the global distribution. The way in which the vaccines are distributed and applied in each country will depend on the decision of the health authority. In the case of Mexico, Cofepris, from the regulatory point of view and from the Ministry of Health ”, he explained.
PFIZER-BIONTECH VACCINE MAY BE FIRST
The leader of scientific and medical affairs for North America of Pfizer’s vaccines division, Alejandro Cané, said that after this Monday, it was reported that in preliminary results his vaccine presented 90 percent efficacy, the hope for the world has a biological that can stop the pandemic.
This report, which is not yet conclusive, emerged in phase three of the clinical trial, which since July has been carried out in six countries with the participation of more than 30,000 people over twelve years of age.
If the estimated production, authorization and distribution times were met, it would become the first vaccine against the SARS-CoV-2 virus.
“The three non-negotiable considerations that the vaccine must meet are: efficacy, safety and high quality standards, without these three conditions the vaccine will not reach people.
“If the results that we are seeing now – because we are the only ones who have shared the preliminary efficacy results – will be like this, but the important thing is not to be the first or the second but to have vaccines available that reach people showing safety and efficacy” , indicated Alejandro Cané.
The Pfizer-Biontech vaccine will be given in two doses with an interval of three weeks, not to exceed 21 days. Immunization was developed with a technology based on the messenger RNA of the virus, which is the copy of the genetic information of the SARS-CoV-2 virus.
MEXICAN GOVERNMENT ANNOUNCED PRE-PURCHASE FROM PFIZER
On November 4, Hugo López-Gatell Ramírez, Undersecretary of Prevention and Health Promotion, reported that Mexico made a pre-purchase with an initial deposit to acquire 51 million vaccines against coronavirus, through the mechanism of Global Access to vaccines against COVID-19, called COVAX, promoted by the World Health Organization (WHO) and other international organizations.
However, he added, these doses are insufficient for the country, so there is the financial capacity to acquire a greater number with three other pre-purchase options, which were negotiated -separately- with the laboratories Pfizer, Astra-Zeneca and CanSino-Biologics.
“The pre-purchase commitments were signed a couple of weeks ago. These pre-purchase commitments, what they allow is to guarantee access. They are not yet contracts, they are commitments that help the Government of Mexico to have timely and facilitated access.
“In all cases, both in the COVAX mechanism and in these three laboratories, it is a non-negotiable matter that if the vaccines do not demonstrate safety, quality and efficacy, they cannot be bought or used in our country,” he explained.
Copyright law strictly prohibits copying all or part of Excelsior materials without first obtaining written permission and without including the link to the original text.